Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-08-30

AUTHORS

Jong Jin Lee , June-Key Chung

ABSTRACT

There are several methods of determining I-131 doses for the treatment of recurrent or metastatic differentiated thyroid cancer, including empirical and dosimetric approaches. The most common and simplest method involves the administration of a fixed empirical dose. Doses are determined by disease extent. The merits of using empirical fixed doses are convenience, a long usage history, a reasonably acceptable rate, and a low severe complication rate. However, some investigators found that patients with metastases that persisted after I-131 therapy received significantly lower radiation doses per millicurie of administered I-131. Thus, dosimetric approaches are needed to ensure the proper management of metastatic DTC. To determine the dose in a given case, we need to know how much activity is contained in a lesion. Lesion mass is another parameter that must be determined for calculation. Dose–response relationships differ, which are due to the difficulty in exact measurement of parameters and due to heterogeneity of radioiodine distribution within metastatic lesions. Another approach is to measure maximal safe dose (MSD), which defined the dose delivering 2 Gy (200 rad) to blood (surrogate of bone marrow). MSD is usually higher than the empirical fixed dose, and this therapy is safe in the treatment of residual DTC. This approach provides a better response rate in metastatic DTC than the conventional fixed dose method. Our data suggest that MSD provides an alternative approach when metastases are refractory to conventional fixed dose therapy. A randomized controlled trial is needed to determine the real efficacy of MSD, and comparative studies are required to evaluate treatment regimens and tumor enhancers, such as retinoic acids. More... »

PAGES

269-274

Book

TITLE

Therapeutic Nuclear Medicine

ISBN

978-3-540-36718-5
978-3-540-36719-2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/174_2012_743

DOI

http://dx.doi.org/10.1007/174_2012_743

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041617520


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jong Jin", 
        "id": "sg:person.01251445402.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251445402.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "June-Key", 
        "id": "sg:person.0751347234.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751347234.39"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-08-30", 
    "datePublishedReg": "2012-08-30", 
    "description": "Abstract\u00a0There are several methods of determining I-131 doses for the treatment of recurrent or metastatic differentiated thyroid cancer, including empirical and dosimetric approaches. The most common and simplest method involves the administration of a fixed empirical dose. Doses are determined by disease extent. The merits of using empirical fixed doses are convenience, a long usage history, a reasonably acceptable rate, and a low severe complication rate. However, some investigators found that patients with metastases that persisted after I-131 therapy received significantly lower radiation doses per millicurie of administered I-131. Thus, dosimetric approaches are needed to ensure the proper management of metastatic DTC. To determine the dose in a given case, we need to know how much activity is contained in a lesion. Lesion mass is another parameter that must be determined for calculation. Dose\u2013response relationships differ, which are due to the difficulty in exact measurement of parameters and due to heterogeneity of radioiodine distribution within metastatic lesions. Another approach is to measure maximal safe dose (MSD), which defined the dose delivering 2 Gy (200 rad) to blood (surrogate of bone marrow). MSD is usually higher than the empirical fixed dose, and this therapy is safe in the treatment of residual DTC. This approach provides a better response rate in metastatic DTC than the conventional fixed dose method. Our data suggest that MSD provides an alternative approach when metastases are refractory to conventional fixed dose therapy. A randomized controlled trial is needed to determine the real efficacy of MSD, and comparative studies are required to evaluate treatment regimens and tumor enhancers, such as retinoic acids.", 
    "editor": [
      {
        "familyName": "Baum", 
        "givenName": "Richard P.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/174_2012_743", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-540-36718-5", 
        "978-3-540-36719-2"
      ], 
      "name": "Therapeutic Nuclear Medicine", 
      "type": "Book"
    }, 
    "keywords": [
      "maximal safe dose", 
      "metastatic DTC", 
      "metastatic differentiated thyroid cancer", 
      "low severe complication rate", 
      "metastatic differentiated thyroid carcinoma", 
      "dosimetric approach", 
      "severe complication rate", 
      "treatment of recurrent", 
      "differentiated thyroid cancer", 
      "differentiated thyroid carcinoma", 
      "better response rate", 
      "dose-response relationship", 
      "dose therapy", 
      "complication rate", 
      "disease extent", 
      "metastatic lesions", 
      "empirical dose", 
      "treatment regimens", 
      "thyroid cancer", 
      "low radiation doses", 
      "dose method", 
      "lesion mass", 
      "tumor enhancer", 
      "thyroid carcinoma", 
      "response rate", 
      "safe dose", 
      "real efficacy", 
      "dose", 
      "therapy", 
      "doses", 
      "retinoic acid", 
      "acceptable rate", 
      "radiation doses", 
      "metastasis", 
      "lesions", 
      "radioiodine distribution", 
      "proper management", 
      "treatment", 
      "regimens", 
      "patients", 
      "carcinoma", 
      "cancer", 
      "recurrent", 
      "administration", 
      "blood", 
      "trials", 
      "DTC", 
      "efficacy", 
      "management", 
      "rate", 
      "investigators", 
      "millicuries", 
      "comparative study", 
      "history", 
      "cases", 
      "activity", 
      "exact measurement", 
      "study", 
      "enhancer", 
      "heterogeneity", 
      "acid", 
      "alternative approach", 
      "mass", 
      "extent", 
      "method", 
      "data", 
      "difficulties", 
      "relationship", 
      "approach", 
      "convenience", 
      "parameters", 
      "simple method", 
      "Abstract", 
      "usage history", 
      "measurements", 
      "distribution", 
      "merits", 
      "calculations"
    ], 
    "name": "Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma", 
    "pagination": "269-274", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041617520"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/174_2012_743"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/174_2012_743", 
      "https://app.dimensions.ai/details/publication/pub.1041617520"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T07:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_94.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/174_2012_743"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/174_2012_743'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/174_2012_743'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/174_2012_743'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/174_2012_743'


 

This table displays all metadata directly associated to this object as RDF triples.

144 TRIPLES      22 PREDICATES      102 URIs      95 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/174_2012_743 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N536a19bcd78442ab8c72b0f783567601
4 schema:datePublished 2012-08-30
5 schema:datePublishedReg 2012-08-30
6 schema:description Abstract There are several methods of determining I-131 doses for the treatment of recurrent or metastatic differentiated thyroid cancer, including empirical and dosimetric approaches. The most common and simplest method involves the administration of a fixed empirical dose. Doses are determined by disease extent. The merits of using empirical fixed doses are convenience, a long usage history, a reasonably acceptable rate, and a low severe complication rate. However, some investigators found that patients with metastases that persisted after I-131 therapy received significantly lower radiation doses per millicurie of administered I-131. Thus, dosimetric approaches are needed to ensure the proper management of metastatic DTC. To determine the dose in a given case, we need to know how much activity is contained in a lesion. Lesion mass is another parameter that must be determined for calculation. Dose–response relationships differ, which are due to the difficulty in exact measurement of parameters and due to heterogeneity of radioiodine distribution within metastatic lesions. Another approach is to measure maximal safe dose (MSD), which defined the dose delivering 2 Gy (200 rad) to blood (surrogate of bone marrow). MSD is usually higher than the empirical fixed dose, and this therapy is safe in the treatment of residual DTC. This approach provides a better response rate in metastatic DTC than the conventional fixed dose method. Our data suggest that MSD provides an alternative approach when metastases are refractory to conventional fixed dose therapy. A randomized controlled trial is needed to determine the real efficacy of MSD, and comparative studies are required to evaluate treatment regimens and tumor enhancers, such as retinoic acids.
7 schema:editor N90d6151e59724eb1ad05e7378e2ca229
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N6adaead14efd4d06b29cf000cfa38b41
11 schema:keywords Abstract
12 DTC
13 acceptable rate
14 acid
15 activity
16 administration
17 alternative approach
18 approach
19 better response rate
20 blood
21 calculations
22 cancer
23 carcinoma
24 cases
25 comparative study
26 complication rate
27 convenience
28 data
29 differentiated thyroid cancer
30 differentiated thyroid carcinoma
31 difficulties
32 disease extent
33 distribution
34 dose
35 dose method
36 dose therapy
37 dose-response relationship
38 doses
39 dosimetric approach
40 efficacy
41 empirical dose
42 enhancer
43 exact measurement
44 extent
45 heterogeneity
46 history
47 investigators
48 lesion mass
49 lesions
50 low radiation doses
51 low severe complication rate
52 management
53 mass
54 maximal safe dose
55 measurements
56 merits
57 metastasis
58 metastatic DTC
59 metastatic differentiated thyroid cancer
60 metastatic differentiated thyroid carcinoma
61 metastatic lesions
62 method
63 millicuries
64 parameters
65 patients
66 proper management
67 radiation doses
68 radioiodine distribution
69 rate
70 real efficacy
71 recurrent
72 regimens
73 relationship
74 response rate
75 retinoic acid
76 safe dose
77 severe complication rate
78 simple method
79 study
80 therapy
81 thyroid cancer
82 thyroid carcinoma
83 treatment
84 treatment of recurrent
85 treatment regimens
86 trials
87 tumor enhancer
88 usage history
89 schema:name Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma
90 schema:pagination 269-274
91 schema:productId N44df8c5a0abb4e1b99d61504fe049ca5
92 Nccb444abc38241d3b40d4091103a10d0
93 schema:publisher N8522bd4e83394086a1f34c0fac37a355
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041617520
95 https://doi.org/10.1007/174_2012_743
96 schema:sdDatePublished 2022-10-01T07:01
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher N0f3b18eedac341b9bf30706896c641e6
99 schema:url https://doi.org/10.1007/174_2012_743
100 sgo:license sg:explorer/license/
101 sgo:sdDataset chapters
102 rdf:type schema:Chapter
103 N042e1fc428794fbd864b481b80842342 schema:familyName Baum
104 schema:givenName Richard P.
105 rdf:type schema:Person
106 N0f3b18eedac341b9bf30706896c641e6 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N2c8538e538624ede920522b78eb3dca2 rdf:first sg:person.0751347234.39
109 rdf:rest rdf:nil
110 N44df8c5a0abb4e1b99d61504fe049ca5 schema:name doi
111 schema:value 10.1007/174_2012_743
112 rdf:type schema:PropertyValue
113 N536a19bcd78442ab8c72b0f783567601 rdf:first sg:person.01251445402.31
114 rdf:rest N2c8538e538624ede920522b78eb3dca2
115 N6adaead14efd4d06b29cf000cfa38b41 schema:isbn 978-3-540-36718-5
116 978-3-540-36719-2
117 schema:name Therapeutic Nuclear Medicine
118 rdf:type schema:Book
119 N8522bd4e83394086a1f34c0fac37a355 schema:name Springer Nature
120 rdf:type schema:Organisation
121 N90d6151e59724eb1ad05e7378e2ca229 rdf:first N042e1fc428794fbd864b481b80842342
122 rdf:rest rdf:nil
123 Nccb444abc38241d3b40d4091103a10d0 schema:name dimensions_id
124 schema:value pub.1041617520
125 rdf:type schema:PropertyValue
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:person.01251445402.31 schema:affiliation grid-institutes:grid.31501.36
133 schema:familyName Lee
134 schema:givenName Jong Jin
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251445402.31
136 rdf:type schema:Person
137 sg:person.0751347234.39 schema:affiliation grid-institutes:grid.31501.36
138 schema:familyName Chung
139 schema:givenName June-Key
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751347234.39
141 rdf:type schema:Person
142 grid-institutes:grid.31501.36 schema:alternateName Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
143 schema:name Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
144 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...